(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...
Results from the GLISTEN study, the largest investigational trial of pruritus in primary biliary cholangitis (PBC), indicate ...
The MarketWatch News Department was not involved in the creation of this content. Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR ...
Distinct lipid changes in primary biliary cholangitis may signal inflammation and fibrosis. Discover how these findings could ...
– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
—Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci ...
Please provide your email address to receive an email when new articles are posted on . International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the ...
—A large international cohort study of patients with primary biliary cholangitis recently demonstrated that the most recent liver stiffness measurement is the single strongest, independent predictor ...
– Livdelzi Data in PBC Participants Provide Outcomes for Long-Term Biochemical Response, which Slows Disease Progression and Sustained Reductions in Chronic Itch, which Impacts Patient Wellbeing and ...
Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...
The treatment is expected to reprogram the immune system to induce tolerance to PDC-E2. The Food and Drug Administration (FDA) has granted Fast Track designation to CNP-104 for the treatment of ...
AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- According to DataM Intelligence, the Primary Biliary Cholangitis (PBC) Treatment Market reached USD 1.33 billion in 2024 and is expected to climb ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback